Mal-PEG4-MMAF is an agent-linker combination designed for antibody-drug conjugates (ADCs), harnessing the robust antitumor efficacy of the potent anti-tubulin agent MMAF. The maleimide reacts with cysteines, and its connection to the MMAF payload is established through the water-soluble PEG4 linkage.
Usually ships within 24 hours.